Navigation Links
Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma
Date:12/11/2011

SAN DIEGO -- Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego.

The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for morning sickness. However, this drug, along with the highly related compounds lenalidomide and pomalidomide, also help to treat blood cancers, and are used worldwide as a cornerstone of therapy for the bone marrow cancer multiple myeloma. These drugs modulate the immune system and together are called immunomodulators or IMiDs.

The exact mechanisms and targets through which these therapies work to enhance immune response or kill cancer cells have been largely unknown. As a result, knowing which patients to treat and how to separate out the positive properties of these drugs from side effects has been impossible.

After recent research identified a protein known as cereblon as a primary mediator of the birth defects caused by thalidomide, researchers theorized that cereblon may also orchestrate the anti-tumor properties and be the primary therapeutic target for multiple myeloma.

In this study, researchers tested the theory and found a possible link between resistance to IMiDs and presence of cereblon. The researchers then found that lowering the level of cereblon allows the IMiDs to work properly.

"Interestingly, some resistant patients had normal cereblon levels, suggesting that while cereblon may be an absolute requirement for response, there are likely other mechanisms present that play a role in drug resistance," says Dr. Stewart. "These findings help us understand which patients may be more or less likely to respond to therapy and allow us to focus on other ways we can target cereblon as a possible biomarker to improve treatment and patient outcomes in multiple myeloma. This work also suggests that we can begin to dissect out the cause of birth defects from the anti-cancer properties and develop safer drugs in the future."


'/>"/>

Contact: Joe Dangor
dangor.yusuf@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
3. Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause
4. Mayo Clinic: Primary physicians may hold key to suicide prevention
5. Mayo Clinic: Short training course significantly improves detection of precancerous polyps
6. Mayo Clinic: Young women with rheumatoid arthritis at more risk for broken bones
7. Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes
8. ICU Patients at Risk for Rare Heart Rhythm Problem
9. Young patients with chronic illnesses find relief in acupuncture
10. For Some Breast Cancer Patients, Shorter Radiation Works Well
11. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2020)... ... May 27, 2020 , ... Radiology ... in the United States, has aligned with the Strategic Radiology (SR) coalition of ... Virginia to join the SR coalition, which has 28 member practices in 20 ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... certain infections can impact the brain causing post infectious encephalitis. The work ... Streptococcal Infections) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack the ...
(Date:5/26/2020)... ... ... Today TRC Companies (“ TRC ”) announced the release of its ... and leaders assess whether their organizations are prepared to move forward as the country ... to assist business leaders evaluate their readiness relative to CDC guidance and provides ideas ...
(Date:5/26/2020)... ... May 26, 2020 , ... As much of the ... United States are joining forces to start a country-wide movement of physical activity ... save lives. #FitForTheFrontLine is a national fitness challenge beginning Tuesday, May 26 and ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... Coordinating Clinical Research, CenterWatch eLearning , https://www.centerwatch.com/products/category/2764-elearning/product/472-the-crc-trainer , Wherever one ... Interactive Companion to the CRC’s Guide to Coordinating Clinical Research provides the ...
Breaking Medicine News(10 mins):
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... continuum, The Beryl Institute releases its latest white paper, Caring for our Children: ... of successful patient experience practices in pediatric settings and highlights key findings to ...
(Date:5/27/2020)... ... , ... Focus Technology , a leading provider of next-generation IT infrastructure, ... sponsor the American Heart Association’s 2020 Boston Heart Walk, earning them the ... firm is sponsoring the AHA event. The sponsorship donation will be used to help ...
(Date:5/26/2020)... ... 26, 2020 , ... Melwood is proud to be donating thousands of vegetable ... pantries, group homes and nursing homes. “It’s more important than ever to reach out ... and bring a little cheer to seniors and individuals of differing abilities,” said Melwood’s ...
Breaking Medicine Technology: